DOCSLIB.ORG

Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models Article Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models Yasuhiro Maruoka, Aki Furusawa , Ryuhei Okada, Fuyuki Inagaki , Daiki Fujimura, Hiroaki Wakiyama , Takuya Kato, Tadanobu Nagaya, Peter L. Choyke and Hisataka Kobayashi * Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA; [email protected] (Y.M.); [email protected] (A.F.); [email protected] (R.O.); [email protected] (F.I.); [email protected] (D.F.); [email protected] (H.W.); [email protected] (T.K.); [email protected] (T.N.); [email protected] (P.L.C.) * Correspondence: [email protected] Received: 4 August 2020; Accepted: 11 September 2020; Published: 14 September 2020 Abstract: Near infrared photoimmunotherapy (NIR-PIT) is a newly developed and highly selective cancer treatment that induces necrotic/immunogenic cell death. It employs a monoclonal antibody (mAb) conjugated to a photo-absorber dye, IRDye700DX, which is activated by NIR light. Tumor-targeting NIR-PIT is also at least partly mediated by a profound immune response against the tumor. Cytotoxic T-lymphocyte antigen-4 (CTLA4) is widely recognized as a major immune checkpoint protein, which inhibits the immune response against tumors and is therefore, a target for systemic blockade. We investigated the effect of combining tumor-targeted NIR-PIT against the cell-surface antigen, CD44, which is known as a cancer stem cell marker, with a systemic CTLA4 immune checkpoint inhibitor in three syngeneic tumor models (MC38-luc, LL/2, and MOC1). CD44-targeted NIR-PIT combined with CTLA4 blockade showed greater tumor growth inhibition with longer survival compared with CTLA4 blockade alone in all tumor models. NIR-PIT and CTLA4 blockade produced more complete remission in MOC1 tumors (44%) than NIR-PIT and programmed cell death protein 1 (PD-1) blockade (8%), which was reported in our previous paper. However, the combination of NIR-PIT and CTLA4 blockade was less effective in MC38-luc tumors (11%) than the combination of NIR-PIT and PD-1 blockade (70%). Nonetheless, in many cases ineffective results with NIR-PIT and PD-1 blockade were reversed with NIR-PIT and CTLA4 blockade. Keywords: near infrared photoimmunotherapy; immune checkpoint blockade; CTLA4; CD44; monoclonal antibodies 1. Introduction Near infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment that induces highly specific cell death in targeted tumor cells. It employs a monoclonal antibody (mAb) conjugated to a silica-phthalocyanine photoabsorbing dye, IRDye700DX (IR700) [1,2]. This antibody-IR700 conjugate is administered intravenously, and after a suitable time to allow for target binding, the tumor is exposed to 690 nm NIR light which activates IR700 [3]. NIR-PIT induces stress on the cellular membrane through photoinduced ligand-release of IR700, leading to impaired membrane function, rapid volume expansion with cell membrane rupture and extrusion of the cell contents into the extracellular space [4,5]. NIR-PIT has an important advantage over other cancer therapies, and induces highly selective necrotic/immunogenic cell death to tumor cells with minimal damage to adjacent normal cells unlike most other conventional cancer therapies that induce apoptotic cell death in both cancer and normal cells [6,7]. A phase III clinical trial of NIR-PIT using the epidermal growth factor receptor (EGFR) -targeted antibody-IR700 conjugate, Vaccines 2020, 8, 0528; doi:10.3390/vaccines8030528 www.mdpi.com/journal/vaccines Vaccines 2020, 8, 0528 2 of 14 cetuximab-IR700, in patients with inoperable head and neck cancer is underway (https://clinicaltrials.gov/ ct2/show/NCT03769506). CD44 is a well-known marker of cancer stem cells [8] and anti-CD44-mAb-IR700 NIR-PIT induces effective tumor killing in CD44-expressing syngeneic mouse models [9–11]. Recently, the combination of CD44-targeted NIR-PIT and programmed cell death protein 1 (PD-1) immune checkpoint blockade was reported to induce massive tumor cell death and innate priming of polyclonal, cancer antigen-specific T-cell responses in several cancer models, resulting in complete tumor rejection and the generation of immunologic memory [10]. However, in some cancer models, CD44-targeted NIR-PIT combined with PD-1 blockade did not show benefits over CD44-targeted NIR-PIT alone. Cytotoxic T-lymphocyte antigen-4 (CTLA4) is a widely recognized immune checkpoint protein, which inhibits the immune response against tumors [12–14], down-regulating T cell activation in response to engagement of the T cell receptor. CTLA4 is expressed transiently on activated T cells, peaking at 2–3 days after initial activation [15], and is always strongly expressed on regulatory T cells (Tregs). Blockade of the interaction between CTLA4 and its ligands, CD80/86 using anti-CTLA4 mAbs can reduce Treg populations leading to increase in effector T cells, thus enhancing anti-tumor immunity [16,17]. CTLA4 and PD-1 blockade, although both intended to enhance anti-tumor immunity, produce distinct immunoregulatory patterns that vary in effectiveness with each tumor model. Therefore, we hypothesized that NIR-PIT combined with CTLA4 blockade could achieve different and perhaps complementary therapeutic effects from NIR-PIT combined with PD-1 blockade. The purpose of this study was to investigate the in vivo therapeutic efficacy of the combination of CD44-targeted NIR-PIT and CTLA4 blockade in several syngeneic mouse models of cancer. 2. Results 2.1. Comfirmation of CD44 Expression as a Target for NIR-PIT and In Vitro Tumor Cell Killing of CD44-Targeted NIR-PIT in MC38-luc, LL/2, and MOC1 Tumor Cells To confirm CD44 expression as a target for NIR-PIT and tumor cell killing effects by CD44-targeted NIR-PIT, flow cytometry and in vitro CD44-targeted NIR-PIT were performed in the three different types of tumor cells (Figure1A–E). Flow-cytometric analysis revealed high fluorescent signal intensity in MC38-luc, LL/2, and MOC1 cells after exposure to anti-CD44-mAb-IR700 (Figure1A,B). This signal was completely reversed in the presence of excess unconjugated anti-CD44-mAb, verifying binding specificity (Figure1A,B). Based on incorporation of propidium iodide (PI), the percentage of cell death increased in a light dose dependent manner in MC38-luc, LL/2, and MOC1 cells (Figure1C–E). There was no significant cytotoxicity associated with NIR light alone in the absence of anti-CD44-mAb-IR700 and with anti-CD44-mAb-IR700 alone without NIR light (Figure1C–E). In MOC 1 cells, relatively high percentage of cells were dead even in untreated samples. This was probably because hash handling was needed to detach MOC1 cells from the plate with a cell scraper due to the strong adhesion. 2.2. Comparison of CD44 Expression among MC38-luc, LL/2, and MOC1 Tumors To compare differences in CD44 expression in vivo among the three different types of tumors, size-matched tumors were assessed by means of immunohistochemical (IHC) staining (Figure2A). CD44 expression was lower in MOC1 tumor tissues than MC38-luc and LL/2 tumors, which has also been demonstrated by flow cytometry analysis in the previous study [10]. The previous study also showed low fluorescence intensity of anti-CD44-mAb-IR700 in MOC1 tumors with quantitative analysis [10]. These suggest that tumor accumulation of anti-CD44-mAb-IR700 1 day after injection as a target antigen is predicted to be lower in MOC1 tumors and direct cell killing by CD44-targeted PIT is expected to be less efficient compared with MC38-luc or LL/2 tumors. We also examined distribution of T cells in the tumor microenvironment of three tumor types. Multiplex IHC showed all three types of tumor had infiltration of CD8 T cells, non-regulatory CD4 T cells and Tregs (Figure2A). MOC1 tumor had significantly more non-regulatory CD4 T cells in the stroma, also, although statistically not Vaccines 2020, 8, 0528 3 of 14 significant, MOC1 had tendency to have smaller number of CD8 T cells and Tregs infiltrating into the tumor (Figure2B). 2.3. Efficacy of CD44-Targeted NIR-PIT Combined with CTLA4 Blockade for MC38-luc Tumor The NIR-PIT regimen and imaging protocol are depicted in Figure3A. In the NIR-PIT treated groups, anti-CD44-mAb-IR700 was administrated one day before the first light exposure (day 1), and the NIR-light − was exposed over the following two days; 50 J/cm2 on day 0 and 100 J/cm2 on day 1 (24 and 48 h after anti-CD44-mAb-IR700 injection, respectively). IR700 fluorescence signal in tumors decreased due to dispersion of fluorophore from dying cells and partial photo-bleaching (Figure3B). To investigate tumor-killing efficacy after NIR-PIT, bioluminescence imaging (BLI) was performed before and after NIR-PIT up to day seven (Figure3E). In most mice luciferase activity decreased immediately after NIR-PIT and then gradually increased over the ensuing days (Figure3E). This implies a large amount of initial cancer cell killing, followed by slower outgrowth of cells not originally killed by NIR-PIT. The effect of the combination group was comparable with that of CD44-targerted NIR-PIT in the BLI images. In all the treated groups, BLI after treatment was significantly lower at all time points after the initial light exposure than in the control group (p < 0.05, Dunnett’s test) (Figure3F). However, there were no significant differences in luciferase activity between CTLA4 mAb alone and combination group and between CD44-targeted NIR-PIT alone and combination groups. In acute phase after treatment, there was no evidence of the success of the combination therapy compared with the single regimens. Tumor volumes in all the treated groups were significantly smaller 2, 5, 7, and 10 days after NIR-PIT compared with the control group (p < 0.05, Dunnett’s test) (Figure3G).
Load more

Recommended publications
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • A Novel Recombinant Anti-CD22 Immunokinase Delivers
    Published OnlineFirst January 29, 2016; DOI: 10.1158/1535-7163.MCT-15-0685 Large Molecule Therapeutics Molecular Cancer Therapeutics A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death- Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells Nils Lilienthal1,2, Gregor Lohmann1, Giuliano Crispatzu1, Elena Vasyutina1, Stefan Zittrich3, Petra Mayer1, Carmen Diana Herling4, Mehmet Kemal Tur5, Michael Hallek4, Gabriele Pfitzer3, Stefan Barth6,7, and Marco Herling1,4 Abstract The serine/threonine death-associated protein kinases (DAPK) SGIII against the B-cell–exclusive endocytic glyco-receptor CD22 provide pro-death signals in response to (oncogenic) cellular stres- was created. Its high purity and large-scale recombinant production ses. Lost DAPK expression due to (epi)genetic silencing is found in a provided a stable, selectively binding, and efficiently internalizing broad spectrum of cancers. Within B-cell lymphomas, deficiency of construct with preserved robust catalytic activity. DK1KD-SGIII the prototypic family member DAPK1 represents a predisposing or specifically and efficiently killed CD22-positive cells of lymphoma early tumorigenic lesion and high-frequency promoter methylation lines and primary CLL samples, sparing healthy donor– or CLL marks more aggressive diseases. On the basis of protein studies and patient–derived non-B cells. The mode of cell death was predom- meta-analyzed gene expression profiling data, we show here that inantly PARP-mediated and caspase-dependent conventional apo- within the low-level context of B-lymphocytic DAPK, particularly ptosis as well as triggering of an autophagic program. The notori- CLL cells have lost DAPK1 expression. To target this potential ously high apoptotic threshold of CLL could be overcome by vulnerability, we conceptualized B-cell–specific cytotoxic reconsti- DK1KD-SGIII in vitro also in cases with poor prognostic features, tution of the DAPK1 tumor suppressor in the format of an immu- such as therapy resistance.
    [Show full text]
  • Bidirectional Crosstalk Between PD-L1 Expression and Epithelial To
    Alsuliman et al. Molecular Cancer (2015) 14:149 DOI 10.1186/s12943-015-0421-2 RESEARCH Open Access Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells Abdullah Alsuliman1, Dilek Colak2, Olfat Al-Harazi2, Hanaa Fitwi1, Asma Tulbah3, Taher Al-Tweigeri4, Monther Al-Alwan1,5 and Hazem Ghebeh1,5* Abstract Background: The T-cell inhibitory molecule PD-L1 (B7-H1, CD274) is expressed on tumor cells of a subset of breast cancer patients. However, the mechanism that regulates PD-L1 expression in this group of patients is still not well-identified. Methods: We have used loss and gain of function gene manipulation approach, multi-parametric flow cytometry, large scale gene expression dataset analysis and immunohistochemistry of breast cancer tissue sections. Results: Induction of epithelial to mesenchymal transition (EMT) in human mammary epithelial cells upregulated PD-L1 expression, which was dependent mainly on the activation of the PI3K/AKT pathway. Interestingly, gene expression signatures available from large cohort of breast tumors showed a significant correlation between EMT score and the PD-L1 mRNA level (p < 0.001). Strikingly, very strong association (p < 0.0001) was found between PD-L1 expression and claudin-low subset of breast cancer, which is known to have high EMT score. On the protein level, significant correlation was found between PD-L1 expression and standard markers of EMT (p =0.005)in67breast cancer patients. Importantly, specific downregulation of PD-L1 in claudin-low breast cancer cells showed signs of EMT reversal as manifested by CD44 and Vimentin downregulation and CD24 upregulation.
    [Show full text]
  • Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)
    Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1) Marcin Kowanetza,1, Wei Zoua, Scott N. Gettingerb, Hartmut Koeppena, Mark Kockxc, Peter Schmidd, Edward E. Kadel IIIa, Ignacio Wistubae, Jamie Chaftf, Naiyer A. Rizvig, David R. Spigelh, Alexander Spirai, Fred R. Hirschj, Victor Cohenk, Dustin Smitha, Zach Boyda, Natasha Mileya, Susan Flynna, Vincent Levequea, David S. Shamesa, Marcus Ballingera, Simonetta Moccia, Geetha Shankara, Roel Funkea, Garret Hamptona, Alan Sandlera, Lukas Amlera, Ira Mellmana,1, Daniel S. Chena, and Priti S. Hegdea aOncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080; bMedical Oncology, Yale Cancer Center, New Haven, CT 06510; cHistoGeneX, 2610 Antwerp, Belgium; dBarts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, United Kingdom; eTranslational Molecular Pathology, MD Anderson Cancer Center, Houston, TX 77054; fMedical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065; gHematology and Oncology, Columbia University, New York, NY 10027; hSarah Cannon Research Institute, Nashville, TN 37203; iOncology Program, Virginia Cancer Specialists, Fairfax, VA 22031; jMedical Oncology, University of Colorado Cancer Center, Denver, CO 80045; and kOncology, Jewish General Hospital, Montreal, QC, Canada H3T 1E2 Edited by Dennis A. Carson, University of California, San Diego, La Jolla, CA, and approved August 21, 2018 (received for review August 21, 2018) Programmed death-ligand 1 (PD-L1) expression on tumor cells cell response, the mechanistic significance of PD-L1 on TC vs. IC (TCs) by immunohistochemistry is rapidly gaining importance as a is unclear. diagnostic for the selection or stratification of patients with non- PD-L1 expression is generally thought to be induced at the small cell lung cancer (NSCLC) most likely to respond to single- transcriptional level after exposure to IFN-γ released by T ef- agent checkpoint inhibitors.
    [Show full text]
  • Differential Antibody Response Against Conformational and Linear Epitopes of the L1 Proteins from Human Papillomavirus Types 16
    Article Differential Antibody Response against Conformational and Linear Epitopes of the L1 Proteins from Human Papillomavirus Types 16/18 Is Observed in Vaccinated Women or with Uterine Cervical Lesions Adolfo Pedroza-Saavedra 1, Angelica Nallelhy Rodriguez-Ocampo 2 , Azucena Salazar-Piña 3 , Aislinn Citlali Perez-Morales 1,4, Lilia Chihu-Amparan 1 , Minerva Maldonado-Gama 1, Aurelio Cruz-Valdez 5, Fernando Esquivel-Guadarrama 4 and Lourdes Gutierrez-Xicotencatl 1,* 1 Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, 62100 Cuernavaca, Mexico; [email protected] (A.P.-S.); [email protected] (A.C.P.-M.); [email protected] (L.C.-A.); [email protected] (M.M.-G.) 2 Unidad Académica Químico Biológicas y Ciencias Farmacéuticas, Universidad Autónoma de Nayarit, 36715 Tepic, Mexico; [email protected] 3 Citation: Pedroza-Saavedra, A.; Facultad de Nutrición, Universidad Autónoma del Estado de Morelos, 62100 Cuernavaca, Mexico; [email protected] Rodriguez-Ocampo, A.N.; 4 Facultad de Medicina, Universidad Autónoma del Estado de Morelos, 62100 Cuernavaca, Mexico; Salazar-Piña, A.; Perez-Morales, A.C.; [email protected] Chihu-Amparan, L.; 5 Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, 62100 Cuernavaca, Maldonado-Gama, M.; Cruz-Valdez, Mexico; [email protected] A.; Esquivel-Guadarrama, F.; * Correspondence: [email protected]; Tel.: +52-77-7329-3086 Gutierrez-Xicotencatl, L. Differential Antibody Response against Abstract: Antibodies against the Human Papillomavirus (HPV) L1 protein are associated with past Conformational and Linear Epitopes infections and related to the evolution of the disease, whereas antibodies against L1 Virus-Like of the L1 Proteins from Human Particles (VLPs) are used to follow the neutralizing antibody response in vaccinated women.
    [Show full text]
  • CDH2 and CDH11 Act As Regulators of Stem Cell Fate Decisions Stella Alimperti A, Stelios T
    Stem Cell Research (2015) 14, 270–282 Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/scr REVIEW CDH2 and CDH11 act as regulators of stem cell fate decisions Stella Alimperti a, Stelios T. Andreadis a,b,⁎ a Bioengineering Laboratory, Department of Chemical and Biological Engineering, University at Buffalo, State University of New York, Amherst, NY 14260-4200, USA b Center of Excellence in Bioinformatics and Life Sciences, Buffalo, NY 14203, USA Received 18 September 2014; received in revised form 24 January 2015; accepted 10 February 2015 Abstract Accumulating evidence suggests that the mechanical and biochemical signals originating from cell–cell adhesion are critical for stem cell lineage specification. In this review, we focus on the role of cadherin mediated signaling in development and stem cell differentiation, with emphasis on two well-known cadherins, cadherin-2 (CDH2) (N-cadherin) and cadherin-11 (CDH11) (OB-cadherin). We summarize the existing knowledge regarding the role of CDH2 and CDH11 during development and differentiation in vivo and in vitro. We also discuss engineering strategies to control stem cell fate decisions by fine-tuning the extent of cell–cell adhesion through surface chemistry and microtopology. These studies may be greatly facilitated by novel strategies that enable monitoring of stem cell specification in real time. We expect that better understanding of how intercellular adhesion signaling affects lineage specification may impact biomaterial and scaffold design to control stem cell fate decisions in three-dimensional context with potential implications for tissue engineering and regenerative medicine. © 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
    [Show full text]
  • Higher Postoperative Plasma EV PD-L1 Predicts Poor Survival in Patients with Gastric Cancer
    Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-002218 on 22 March 2021. Downloaded from Higher postoperative plasma EV PD- L1 predicts poor survival in patients with gastric cancer Gaopeng Li,1 Guoliang Wang,2 Fenqing Chi,3 Yuqi Jia,3 Xi Wang,3 Quankai Mu,3 Keru Qin,3 Xiaoxia Zhu,3 Jing Pang,3 Baixue Xu,3 Guangen Feng,3 Yuhu Niu,3 Tao Gong,3 Hongwei Zhang,4 Xiushan Dong,5 Ting Liu,6 Jinfeng Ma,6 Zefeng Gao,6 7 8 9 3 Kai Tao, Feng Li, Jun Xu, Baofeng Yu To cite: Li G, Wang G, Chi F, ABSTRACT as carcinoembryonic antigen (CEA), cancer et al. Higher postoperative Background The satisfactory prognostic indicator of antigen 72–4 (CA72-4) and cancer antigen plasma EV PD- L1 predicts gastric cancer (GC) patients after surgery is still lacking. 19–9 CA19-9 (CA19-9), lack sufficient discrim- poor survival in patients with Perioperative plasma extracellular vesicular programmed gastric cancer. Journal for ination to distinguish patients with good or cell death ligand-1 (ePD- L1) has been demonstrated as a 6–8 ImmunoTherapy of Cancer poor prognosis. In addition to pathological potential prognosis biomarker in many types of cancers. 2021;9:e002218. doi:10.1136/ TNM (TumorNode Metastasis) staging, there jitc-2020-002218 The prognostic value of postoperative plasma ePD-L1 has not been characterized. still lack satisfactory prognostic indicators of Methods We evaluated the prognostic value of GC patients after surgery, which is critically ► Additional material is published online only. To view, preoperative, postoperative and change in plasma ePD- L1, important in determine optimal postopera- please visit the journal online as well as plasma soluble PD-L1, in short-term survival of tive strategies.
    [Show full text]
  • Theranostics Gastric Cancer Mesenchymal Stem Cells Regulate
    Theranostics 2020, Vol. 10, Issue 26 11950 Ivyspring International Publisher Theranostics 2020; 10(26): 11950-11962. doi: 10.7150/thno.49717 Research Paper Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis Li Sun1, 2*, Chao Huang1*, Miaolin Zhu3, Shuwei Guo1, Qiuzhi Gao1, Qianqian Wang1, Bin Chen1, Rong Li1, Yuanyuan Zhao1, Mei Wang1, Zhihong Chen4, Bo Shen3, Wei Zhu1 1. School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China 2. Department of Clinical Laboratory, Kunshan First People's Hospital, Affiliated to Jiangsu University, Kunshan, Jiangsu, China 3. Department of Oncology, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China 4. Department of Gastrointestinal Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China *Li Sun and Chao Huang contributed equally to this work. Corresponding author: Wei Zhu, PhD. School of Medicine, Jiangsu University, 301 Xuefu Road, Zhenjiang, Jiangsu, 212013, China.E-mail: [email protected]. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.06.20; Accepted: 2020.10.10; Published: 2020.10.25 Abstract Rationale: Mesenchymal stem cells (MSCs) have been the focus of many studies because of their abilities to modulate immune responses, angiogenesis, and promote tumor growth and metastasis. Our previous work showed that gastric cancer MSCs (GCMSCs) promoted immune escape by secreting of IL-8, which induced programmed cell death ligand 1 (PD-L1) expression in GC cells.
    [Show full text]
  • Dexamethasone-Induced Insulin Resistance in 3T3-L1 Adipocytes Is
    Dexamethasone-Induced Insulin Resistance in 3T3-L1 Adipocytes Is Due to Inhibition of Glucose Transport Rather Than Insulin Signal Transduction Hideyuki Sakoda, Takehide Ogihara, Motonobu Anai, Makoto Funaki, Kouichi Inukai, Hideki Katagiri, Yasushi Fukushima, Yukiko Onishi, Hiraku Ono, Midori Fujishiro, Masatoshi Kikuchi, Yoshitomo Oka, and Tomoichiro Asano Glucocorticoids reportedly induce insulin resistance. In ment clearly inhibited the increases in glucose uptake this study, we investigated the mechanism of glucocor- produced by these agents. Thus, in conclusion, the ticoid-induced insulin resistance using 3T3-L1 adip- GLUT1 decrease may be involved in the dexametha- ocytes in which treatment with dexamethasone has sone-induced decrease in basal glucose transport activ- been shown to impair the insulin-induced increase in ity, and the mechanism of dexamethasone-induced glucose uptake. In 3T3-L1 adipocytes treated with dex- insulin resistance in glucose transport activity (rather amethasone, the GLUT1 protein expression level was than the inhibition of phosphatidylinositol 3-kinase decreased by 30%, which possibly caused decreased activation resulting from a decreased IRS-1 content) is basal glucose uptake. On the other hand, dexametha- likely to underlie impaired glucose transporter regula- sone treatment did not alter the amount of GLUT4 pro- tion. Diabetes 49:1700–1708, 2000 tein in total cell lysates but decreased the insulin-stim- ulated GLUT4 translocation to the plasma membrane, which possibly caused decreased insulin-stimulated glucose uptake. Dexamethasone did not alter tyrosine phosphorylation of insulin receptors, and it significantly esearch has shown that glucocorticoids are hor- decreased protein expression and tyrosine phospho- mones that induce insulin resistance and that rylation of insulin receptor substrate (IRS)-1.
    [Show full text]
  • Predicting Pathogenicity of CDH1 Gene Variants in Patients with Early-Onset Diffuse Gastric Cancer from Western Mexico
    REVISTA DE INVESTIGACIÓN CLÍNICA Contents available at PubMed www.clinicalandtranslationalinvestigation.com Rev Invest Clin. 2021;73(3):172-81 ORIGINAL ARTICLE Predicting Pathogenicity of CDH1 Gene Variants in Patients with Early-onset Diffuse Gastric Cancer from Western Mexico Azaria García-Ruvalcaba1,2, Lourdes del C. Rizo de la Torre3, María T. Magaña-Torres1, Ernesto Prado-Montes-de-Oca4,5,6, Andrea V. Ruiz-Ramírez1,2,4, Héctor Rangel-Villalobos7, José A. Aguilar-Velázquez2,7, Andrea M. García-Muro1,2, and Josefina Y. Sánchez-López1* 1Genetics Division, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jal.; 2Doctorate Program in Human Genetics, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jal.; 3Molecular Medicine Division, Centro de Investigación Biomédica de Occidente, IMSS, Guadalajara, Jal.; ⁴Laboratory of Regulatory SNPs, Personalized Medicine Laboratory, Medical and Pharmaceutical Biotechnology, Research and Assistance Center in Technology and Design of Jalisco A.C. (CIATEJ AC), Consejo Nacional de Ciencia y Tecnología (CONACyT), Guadalajara, Jal.; 5Scripps Research Translational Institute, La Jolla, California, USA; 6Integrative Structural and Computational Biology, Scripps Research La Jolla, California, USA; 7Department of Medical and Life Sciences, Instituto de Investigación en Genética Molecular, Centro Universitario de la Ciénega, Universidad de Guadalajara, Guadalajara, Jal., Mexico ABSTRACT Background: Early-onset diffuse gastric cancer (EODGC) occurs at or before 50 years of age. Pathogenic mutations and germ- line deletions in the CDH1 gene (E-cadherin) are well-documented genetic factors associated with the causes of EODGC. Objec- tive: The objective of the study was to study CDH1 germline variants and their potential functional impact in patients with EODGC in a Mexican population.
    [Show full text]
  • Inhibition of Adipogenesis in 3T3-L1 Cells and Suppression of Abdominal
    International Journal of Obesity (2014) 38, 1035–1043 & 2014 Macmillan Publishers Limited All rights reserved 0307-0565/14 www.nature.com/ijo ORIGINAL ARTICLE Inhibition of adipogenesis in 3T3-L1 cells and suppression of abdominal fat accumulation in high-fat diet-feeding C57BL/6J mice after downregulation of hyaluronic acid EJi1,5, MY Jung1,5, JH Park2, S Kim1, CR Seo1, KW Park1, EK Lee3, CH Yeom4 and S Lee1 OBJECTIVE: Adipogenesis can be spatially and temporally regulated by extracellular matrix (ECM). We hypothesized that the regulation of hyaluronic acid (HA), a component of the ECM, can affect adipogenesis in fat cells. The effects of HA on adipogenesis were investigated in vitro in 3T3-L1 cells and in vivo in high-fat diet-feeding C57BL/6J mice. METHODS: We investigated the effects of HA by degradation of pre-existing or synthesized HA and artificial inhibition of HA synthesis in adipogenesis. RESULTS: In vitro adipogenesis in 3T3-L1 cells was inhibited by treating them with exogenous hyaluronidase (HYAL) and with 4-methylumbelliferone, which inhibited the synthesis of HA in a concentration-dependent manner. In vivo, abdominal fat accumulation in high-fat diet-feeding C57BL/6J mice was suppressed by exogenous HYAL 104 IU injections, which was associated with reduction of lipid accumulation in liver and increase of insulin sensitivity. CONCLUSION: Changes in the ECM such as accumulation of high molecular weight of HA by HAS and degradation of HA by endogenous HYAL were essential for adipogenesis both in vitro and in vivo. International Journal of Obesity (2014) 38, 1035–1043; doi:10.1038/ijo.2013.202 Keywords: extracellular matrix; hyaluronic acid; adipogenesis; 3T3-L1 cells; high-fat diet-induced obesity INTRODUCTION cytoskeletal elements is necessary for the transformation of 11–13 Obesity is defined as a condition in which excessive fat accumulates pre-adipocytes into mature adipocytes.
    [Show full text]
  • Anlotinib Alters Tumor Immune Microenvironment By
    Liu et al. Cell Death and Disease (2020) 11:309 https://doi.org/10.1038/s41419-020-2511-3 Cell Death & Disease ARTICLE Open Access anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells Shaochuan Liu1,2,3,4, Tingting Qin1,2,3,4, Zhujun Liu1,2,3,4,JingWang1,2,3,4, Yanan Jia1,2,3,4,YingfangFeng1,2,3,4, Yuan Gao1,2,3,4 and Kai Li1,2,3,4 Abstract Aberrant vascular network is a hallmark of cancer. However, the role of vascular endothelial cells (VECs)-expressing PD- L1 in tumor immune microenvironment and antiangiogenic therapy remains unclear. In this study, we used the specimens of cancer patients for immunohistochemical staining to observe the number of PD-L1+ CD34+ VECs and infiltrated immune cells inside tumor specimens. Immunofluorescence staining and flow cytometry were performed to observe the infiltration of CD8+ T cells and FoxP3+ T cells in tumor tissues. Here, we found that PD-L1 expression on VECs determined CD8+ T cells’, FoxP3+ T cells’ infiltration, and the prognosis of patients with lung adenocarcinoma. Anlotinib downregulated PD-L1 expression on VECs through the inactivation of AKT pathway, thereby improving the ratio of CD8/FoxP3 inside tumor and remolding the immune microenvironment. In conclusion, our results demonstrate that PD-L1 high expression on VECs inhibits the infiltration of CD8+ T cells, whereas promotes the aggregation of FoxP3+ T cells into tumor tissues, thus becoming an “immunosuppressive barrier”. Anlotinib can ameliorate the immuno-microenvironment by downregulating PD-L1 expression on VECs to inhibit tumor growth.
    [Show full text]